Aligos Therapeutics (ALGS) Price & Analysis

Compare

242 Followers

ALGS Stock Chart & Stats

$7.53

-$2.78(-6.79%)

At close: Jan 08 4:00 PM EST

$7.53

-$2.78(-6.79%)

Day’s Range― - ―

52-Week Range$3.76 - $46.80

Previous CloseN/A

Volume178.18K

Average Volume (3M)86.97K

Market Cap

$61.45M

Enterprise Value-$41.55M

Total Cash (Recent Filing)$123.06M

Total Debt (Recent Filing)$6.88M

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Mar 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding5,351,374

10 Day Avg. Volume122,947

30 Day Avg. Volume86,969

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.68

Enterprise Value/Revenue-13.09

Enterprise Value/Gross Profit-18.51

Enterprise Value/Ebitda0.57

Forecast

1Y Price Target

$50.00

Price Target Upside564.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Chronic Hepatitis B Virus (HBV) TreatmentALG-000184 has the potential to become the new standard-of-care for chronic suppression of hepatitis B virus, serving as the oral backbone to future functional cure regimens.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) TreatmentRoche’s agreement to acquire 89bio for up to ~$3.5B underscores intensifying large-cap conviction in Metabolic Dysfunction-Associated Steatohepatitis (MASH) and combination strategies—providing a positive read-through to Aligos’ ALG-055009.

Strategic Partnering And DevelopmentManagement noted the goal of securing a transaction in 2026 for ALG-055009 that could provide non-dilutive funding and accelerate development.

Bears Say

Clinical Development RisksRisks include clinical development risk for ALG-000184, particularly if future studies show safety concerns, resistance, or diminished biomarker effects.

Financing RisksFinancing risk given Aligos’ cash runway into 2H26, and the potential for additional equity issuance to support Phase 2b and Phase 3 activities.

Aligos Therapeutics News

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options...

20d ago

ALGS

Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium

Aligos Therapeutics (ALGS) announced that the United States Adopted Names, USAN, Council has adopted pevifoscorvir sodium as the...

21d ago

ALGS

Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?

Aligos Therapeutics, Inc. (($ALGS)) announced an update on their ongoing clinical study. Study Overview: Aligos Therapeutics, Inc. is...

9d ago

ALGS

Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Aligos Therapeutics today and set a price target...

27d ago

ALGS

Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Aligos Therapeutics. The associated price target...

2M ago

ALGS

Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs

Aligos Therapeutics (ALGS) announced the appointment of Ramon Polo as Senior Vice President, Head of Global Regulatory Affairs,...

3M ago

ALGS

Aligos Therapeutics: Promising Advancements in HBV Treatment and Strategic Pipeline Growth

Patrick Trucchio, an analyst from H.C. Wainwright, has initiated a new Buy rating on Aligos Therapeutics (ALGS). Patrick...

3M ago

ALGS

Aligos Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Aligos Therapeutics (ALGS) with a Buy rating and $50 price target The firm...

3M ago

ALGS

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options...

3M ago

ALGS

Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study

Aligos Therapeutics (ALGS) announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has...

3M ago

ALGS

Aligos Therapeutics Reports Q2 2025 Progress and Results

Aligos Therapeutics, Inc. ( ($ALGS) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

ALGS

Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)

Reports Q2 revenue $965,000, consensus $433,330. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway...

3M ago

ALGS

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options...

4M ago

ALGS

Aligos Therapeutics Approves Major Amendments at Annual Meeting

An update from Aligos Therapeutics ( ($ALGS) ) is now available. On June 25, 2025, Aligos Therapeutics, Inc....

4M ago

ALGS

ALGS FAQ

What was Aligos Therapeutics’s price range in the past 12 months?

Aligos Therapeutics lowest stock price was $3.76 and its highest was $46.80 in the past 12 months.

What is Aligos Therapeutics’s market cap?

Aligos Therapeutics’s market cap is $61.45M.

When is Aligos Therapeutics’s upcoming earnings report date?

Aligos Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 119 days.

How were Aligos Therapeutics’s earnings last quarter?

Currently, no data Available

Is Aligos Therapeutics overvalued?

According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aligos Therapeutics pay dividends?

Aligos Therapeutics does not currently pay dividends.

What is Aligos Therapeutics’s EPS estimate?

Aligos Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aligos Therapeutics have?

Aligos Therapeutics has 5,351,374 shares outstanding.

What happened to Aligos Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aligos Therapeutics?

Currently, no hedge funds are holding shares in ALGS

Aligos Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-87.74%

Trailing 12-Months

Asset Growth

23.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aligos Therapeutics

Aligos Therapeutics (ALGS) is a biotechnology company focused on developing innovative therapies for viral infections and liver diseases. The company primarily operates in the biopharmaceutical sector, with a particular emphasis on hepatitis B and other liver-related conditions. Aligos is known for its proprietary technology platforms that facilitate the discovery and development of novel therapeutics aimed at addressing unmet medical needs in these areas.

Aligos Therapeutics (ALGS) Earnings & Revenues

Historic Earnings Reports

ALGS Stock 12 Month Forecast

Average Price Target

$50.00

▲(564.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","51":"$51","15.75":"$15.75","27.5":"$27.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,15.75,27.5,39.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.29,13.344615384615384,16.39923076923077,19.45384615384615,22.50846153846154,25.56307692307692,28.617692307692305,31.67230769230769,34.72692307692307,37.78153846153846,40.83615384615385,43.89076923076923,46.94538461538461,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.29,13.344615384615384,16.39923076923077,19.45384615384615,22.50846153846154,25.56307692307692,28.617692307692305,31.67230769230769,34.72692307692307,37.78153846153846,40.83615384615385,43.89076923076923,46.94538461538461,{"y":50,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.29,13.344615384615384,16.39923076923077,19.45384615384615,22.50846153846154,25.56307692307692,28.617692307692305,31.67230769230769,34.72692307692307,37.78153846153846,40.83615384615385,43.89076923076923,46.94538461538461,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.87,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >